by Jon Fleetwood, Jon Fleetwood:
MFLUSIVA triggers six times more severe reactions for less than 1% absolute benefit, Moderna scientists admitted last month in the New England Journal of Medicine.
The U.S. Food and Drug Administration (FDA) has scheduled a June 18, 2026 advisory committee meeting to publicly review the “safety and effectiveness” of Moderna’s new mRNA pandemic influenza vaccine MFLUSIVA (mRNA-1010) for adults age 50 and older, according to a new Federal Register notice.
Moderna’s own scientists confirmed in a May New England Journal of Medicine publication that MFLUSIVA triggers six times more severe reactions for less than 1% absolute benefit.
TRUTH LIVES on at https://sgtreport.tv/
That means mRNA-1010 caused far more severe side effects while reducing flu illness by less than 1% compared to the standard flu shot used in the study, raising serious questions about whether the increased reactogenicity and risk profile are justified by such a minimal reduction in influenza illness.
The vaccine manufacturer explicitly categorizes MFLUSIVA as a “pandemic influenza vaccine candidate” meant for a “future pandemic.”
HHS is moving forward with Moderna’s injectable “solution” for a future-declared influenza pandemic while simultaneously funding the purported creation of lab-engineered chimeric influenza pathogens with immune system-evading traits, and ones with mutations helping them adapt to mammals.
Congress, the White House, the Department of Energy, the FBI, the CIA, and Germany’s Federal Intelligence Service (BND) all acknowledged that the deadly COVID-19 pandemic was “likely” the result of a laboratory incident involving engineered pathogens.
The upcoming meeting will be conducted virtually and livestreamed on YouTube, with the FDA stating the Vaccines and Related Biological Products Advisory Committee (VRBPAC) will “discuss and make recommendations” on Moderna’s Biologics License Application (STN 125869/0) for the vaccine.
The filing specifically states the vaccine is an “Influenza Vaccine, mRNA” manufactured by Moderna TX Inc. and is being proposed for “the prevention of influenza disease caused by influenza virus subtypes A and type B represented in the vaccine, in persons 50 years of age and older.”
The FDA opened a public comment docket that closes June 17, 2026.
Comments submitted by June 12 will be provided directly to the advisory committee members before the meeting.
Read More @ jonfleetwood.substack.com
